Oramed Pharmaceuticals (ORMP) Expected to Release Quarterly Earnings on Thursday

Key Points

• Oramed is expected to report Q3 2026 results before market open on Thursday, November 12, with analysts forecasting earnings of $0.43 per share; its earnings call is scheduled for November 13 at 4 p.m. ET.
• In its prior quarter, the company reported a loss of $0.09 per share, missing the $0.43 consensus estimate by $0.52.
• MarketBeat reports an average analyst rating of “Buy.” The CFO and COO each sold shares under pre-arranged trading plans on October 1, while insiders collectively own 20.77% of the stock.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Oramed Pharmaceuticals to announce earnings of $0.43 per share for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.52).

Oramed Pharmaceuticals Price Performance

ORMP stock opened at $4.13 on Thursday. Oramed Pharmaceuticals has a 1-year low of $2.09 and a 1-year high of $5.47. The firm has a fifty day moving average price of $4.51 and a two-hundred day moving average price of $4.03. The firm has a market cap of $171.81 million, a price-to-earnings ratio of 1.00 and a beta of 1.31.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Weiss Ratings raised shares of Oramed Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday, October 23rd. Wall Street Zen upgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. One analyst has rated the stock with a Buy rating. According to data from MarketBeat.com, Oramed Pharmaceuticals currently has an average rating of "Buy".

Insider Buying and Selling

In other Oramed Pharmaceuticals news, CFO Avraham Gabay sold 20,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $90,200.00. Following the sale, the chief financial officer directly owned 861,076 shares of the company's stock, valued at $3,883,452.76. This trade represents a 2.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joshua Hexter sold 30,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $135,300.00. Following the completion of the sale, the chief operating officer directly owned 1,328,130 shares in the company, valued at $5,989,866.30. This represents a 2.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.77% of the company's stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc NASDAQ: ORMP is a biopharmaceutical company focused on developing oral formulations of drugs that are typically administered by injection. The company's proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from degradation in the digestive system and facilitate their absorption through the gastrointestinal tract.

Oramed's development programs have primarily focused on oral insulin, including its investigational ORMD-0801 product candidate for the treatment of diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.